Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer
RARITAN, NJ, March 10, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. JNJ-6372 is an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications. Currently, there are no FDA-approved targeted therapies for patients with lung cancer who have EGFR Exon 20 insertion mutations.Patients with NSCLC and EGFR Exon 20 insertion mutations have a form of disease that is generally insensitive to EGFR tyrosine kinase inhibitor (TKI) treatments and carries a worse prognosis compared to patients with more common EGFR mutations (Exon 19 deletions/L858R substitution). The current standard of care for this patient population is conventional cytotoxic chemotherapy. “JNJ-6372 is a novel bispecific antibody that we believe has the potential to benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies,” said Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research &Devel...
Publication date: Available online 24 May 2020Source: Journal of Vascular and Interventional RadiologyAuthor(s): Kasey Halsey, Jing Wu, Chang Su, Ben Hsieh, Thomas Yi, Scott A. Collins, Benjamin Kimia, Paul J. Zhang, Terrance Healey, Zishu Zhang, Harrison X. Bai
Publication date: Available online 24 May 2020Source: European Journal of RadiologyAuthor(s): Lisa Loi, Ferdinand Zimmermann, Steffen Goerke, Andreas Korzowski, Jan-Eric Meissner, Katerina Deike-Hofmann, Anne Stieber, Peter Bachert, Mark Edward Ladd, Heinz-Peter Schlemmer, Sebastian Bickelhaupt, Sarah Schott, Daniel Paech
ConclusionThe proposed multiparametric MRI-based SLICs+MTh method performs noninvasive assessment of NACT response in osteosarcoma that may improve cancer treatment monitoring, planning, and overall prognosis.Key Points• The simple linear iterative clustering supervoxels and Otsu multithresholding-based technique (SLICs+MTh) successfully estimates the proportion of necrosis, viable tumor, and edema in osteosarcoma in the course of chemotherapy.• The proposed technique is noninvasive and uses multiparametric MRI to measure necrosis as an indication of anticancer treatment response.• SLICs+MTh-based necrosis w...
Publication date: Available online 24 May 2020Source: Pathology - Research and PracticeAuthor(s): Tania Franceschini, Elisa Capizzi, Francesco Massari, Riccardo Schiavina, Michelangelo Fiorentino, Francesca Giunchi
Publication date: May 2020Source: Journal of Comparative Pathology, Volume 177Author(s): L.M.C. Soares, A.H.B. Pereira, C.G. de Campos, L.S. Rocha, T.Á. dos Santos, M.A. Souza, P.C. Jark, C.A. Pescador
Psychologists say anxiety and uncertainty prompt irrational decisions — like turning down a transplant when an organ becomes available.
HIGH BLOOD PRESSURE may seem harmless but the condition can be a precursor to heart disease so it is important to keep it in check. Nuts have been shown to have a moderating effect on blood pressure and one nut comes out on top.
Publication date: 5 August 2020Source: Journal of Pharmaceutical and Biomedical Analysis, Volume 187Author(s): Valentina Iacuzzi, Martina Zanchetta, Sara Gagno, Ariana Soledad Poetto, Marco Orleni, Elena Marangon, Michela Guardascione, Luisa Foltran, Bianca Posocco, Giuseppe Toffoli
Publication date: August 2020Source: Biomedicine &Pharmacotherapy, Volume 128Author(s): Qingzhi Guo, Li Li, Qimei Bo, Li Chen, Li Sun, Hongtang Shi
Publication date: Available online 24 May 2020Source: Canadian Journal of CardiologyAuthor(s): Blake Sandery, Janis M. Dionne
More News: Adenocarcinoma | Allergy & Immunology | Biotechnology | Brain | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cardiology | Cardiovascular | Chemotherapy | Drugs & Pharmacology | Epithelial Cancer | Food and Drug Administration (FDA) | Genetics | Health Management | Heart | Hypertension | Infectious Diseases | Learning | Legislation | Lung Cancer | Neurology | Neuroscience | Non-Small Cell Lung Cancer | Oral Cancer | Pharmaceuticals | Pulmonary Hypertension | Science | Skin | Skin Cancer | Squamous Cell Carcinoma | Statistics | Study | Universities & Medical Training | Vaccines | Women